KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Non-Current Deferred Tax Liability (2016 - 2025)

Amgen has reported Non-Current Deferred Tax Liability over the past 12 years, most recently at $1.4 billion for Q4 2025.

  • Quarterly results put Non-Current Deferred Tax Liability at $1.4 billion for Q4 2025, down 15.47% from a year ago — trailing twelve months through Dec 2025 was $1.4 billion (down 15.47% YoY), and the annual figure for FY2025 was $1.4 billion, down 15.47%.
  • Non-Current Deferred Tax Liability for Q4 2025 was $1.4 billion at Amgen, down from $1.5 billion in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for AMGN hit a ceiling of $2.4 billion in Q4 2023 and a floor of $1.4 billion in Q4 2025.
  • Median Non-Current Deferred Tax Liability over the past 4 years was $1.7 billion (2024), compared with a mean of $1.7 billion.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: rose 25.48% in 2023 and later crashed 31.35% in 2024.
  • Amgen's Non-Current Deferred Tax Liability stood at $1.9 billion in 2022, then rose by 25.48% to $2.4 billion in 2023, then crashed by 31.35% to $1.6 billion in 2024, then decreased by 15.47% to $1.4 billion in 2025.
  • The last three reported values for Non-Current Deferred Tax Liability were $1.4 billion (Q4 2025), $1.5 billion (Q3 2025), and $1.4 billion (Q2 2025) per Business Quant data.